Triple-negative breast cancer (TNBC) accounts for 10-15% of breast cancers and is managed primarily with chemotherapy and immune checkpoint inhibitors; however, treatment responses remain variable and these patients are at higher risk of cancer recurrence compared to patients with hormone receptor-positive or HER2-positive breast cancer. Here, NR4A1 is linked to triple-negative breast carcinoma.